Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA.
Target Price
The average target price of ZYME is 35 and suggests 51% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell